Please login to the form below

Not currently logged in
Email:
Password:

Neurimmune appoints chief business officer

Fabian Buller will further drive the biopharma’s growth strategy

Monoclonal antibody-focused Neurimmune has appointed Fabian Buller into the newly created role of chief business officer.

Buller joins the biopharmaceutical group’s executive team, bringing with him eight years of biotech and pharma experience.

Prior to joining Neurimmune, Buller served as director new ventures at Johnson & Johnson Innovation, as well as director of business development of Covagen.

Roger Nitsch, president and CEO of Neurimmune, said: “We are pleased that Dr Buller joins our company to further drive our growth strategy.

“Dr Buller has an impressive track record in business development and licensing transactions.

“He will play a key role in realising opportunities that will allow us to bring novel therapeutics to patients.”

2nd May 2018

From: PME

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics